The recent and historic $160 billion mega-merger of U.S. drug house Pfizer and Allergan allows Pfizer to dodge American taxes. Why pharmaceutical tax dodging of this nature isn't a concern of all current presidential candidates is anyone's guess. The recent merger allows Pfizer to relocate its headquarters to Ireland, where Allergan is incorporated and the tax rate for corporations is 12.5% — less than the U.S. rate of 39.2%. For Pfizer, it means taxes will go as low as 17%. Using Pfizer's 2014 financial report earnings, they would now be paying $8,432,000,000 in taxes instead of $19,344,000,000.